Literature DB >> 8980295

Molecular subtyping of Borrelia burgdorferi sensu lato isolates from five patients with solitary lymphocytoma.

R N Picken1, F Strle, E Ruzic-Sabljic, V Maraspin, S Lotric-Furlan, J Cimperman, Y Cheng, M M Picken.   

Abstract

Solitary lymphocytoma is a rare cutaneous manifestation of Lyme borreliosis that has been reported almost exclusively from Europe. This suggests that its etiologic agent may be absent or extremely rare on the North American continent. All three species of B. burgdorferi sensu lato known to be associated with human Lyme borreliosis (B. burgdorferi sensu stricto, B. garinii, and B. afzelii have been isolated in Europe, whereas only B. burgdorferi sensu stricto has been found in North America. This suggests that either B. garinii or B. afzelii might be the etiologic agent of borrelial lymphocytoma. To investigate this hypothesis we characterized five strains of B. burgdorferi sensu lato isolated from lymphocytoma lesions of patients residing in Slovenia. The methods used included: large restriction fragment pattern analysis of restriction enzyme MluI-digested genomic DNA, plasmid profiling, protein profiling, ribotyping using 5S, 16S, and 23S rDNA probes, and polymerase chain reaction amplification of the rrf (5S)-rrl (23S) intergenic spacer region. Molecular subtyping showed that four of the five isolates belonged to the species B. afzelii; however, this species is the predominant patient isolate in Slovenia and, therefore, may not represent a preferential association with lymphocytoma. The fifth isolate appeared to be most closely related to the DN127 genomic group of organisms. Further characterization of the isolate revealed that it possessed a unique molecular "fingerprint." The results not only show that borrelial lymphocytoma can be caused by B. afzelii but also demonstrate an association with another genomic group of B. burgdorferi sensu lato that is present in North America as well.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8980295     DOI: 10.1111/1523-1747.ep12285646

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas.

Authors:  Maurilio Ponzoni; Andrés J M Ferreri; Silvia Mappa; Elisa Pasini; Silvia Govi; Fabio Facchetti; Daniele Fanoni; Alessandra Tucci; Arianna Vino; Claudio Doglioni; Emilio Berti; Riccardo Dolcetti
Journal:  Oncologist       Date:  2011-11-09

Review 2.  Borrelial lymphocytoma.

Authors:  Vera Maraspin; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2022-08-09       Impact factor: 2.275

3.  Borrelial lymphocytoma cutis: a diagnostic dilemma.

Authors:  Rajat Kandhari; Sanjiv Kandhari; Sudhir Jain
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

4.  PCR-reverse line blot typing method underscores the genomic heterogeneity of Borrelia valaisiana species and suggests its potential involvement in Lyme disease.

Authors:  Edmond Godfroid; Chang Min Hu; Pierre-François Humair; Alex Bollen; Lise Gern
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

5.  Borrelia burgdorferi infection and cutaneous Lyme disease, Mexico.

Authors:  Guadalupe Gordillo-Pérez; Javier Torres; Fortino Solórzano-Santos; Sylvie de Martino; Dan Lipsker; Edmundo Velázquez; Guillermo Ramon; Muñoz Onofre; Benoit Jaulhac
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

6.  Lyme borreliosis and skin.

Authors:  Biju Vasudevan; Manas Chatterjee
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

7.  Damage of collagen and elastic fibres by borrelia burgdorferi - known and new clinical and histopathological aspects.

Authors:  Kurt E Müller
Journal:  Open Neurol J       Date:  2012-12-31

Review 8.  Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?

Authors:  Yann Vincent Charli-Joseph; Michelle Gatica-Torres; Laura Beth Pincus
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.